Galenica AG (GALNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Galenica AG (GALNF) with AI Score 46/100 (Weak). Galenica AG is a Swiss healthcare provider operating through Products & Care and Logistics & IT segments. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Galenica AG (GALNF) Healthcare & Pipeline Overview
Galenica AG, a Swiss healthcare leader, operates pharmacies under brands like Amavita and Sun Store, alongside providing logistics and IT solutions to the pharmaceutical industry. With a focus on integrated healthcare services, Galenica leverages its distribution network and pharmacy operations to maintain a strong position in the Swiss healthcare market.
Investment Thesis
Galenica AG presents a compelling investment case based on its integrated healthcare service model and strong market position in Switzerland. With a market capitalization of $6.17 billion and a healthy ROE of 12.1%, the company demonstrates financial stability. Growth catalysts include expansion of its pharmacy network and increased demand for its logistics and IT services. A potential risk factor is the competitive landscape in the Swiss healthcare market. The company's consistent profitability, indicated by a 4.4% profit margin, and its established infrastructure support a positive long-term outlook. The debt-to-equity ratio of 70.09% should be monitored for potential financial strain.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $6.17 billion reflects substantial investor confidence in Galenica AG's market position.
- Profit margin of 4.4% indicates consistent profitability in the competitive healthcare sector.
- Gross margin of 12.2% demonstrates the company's ability to manage costs effectively.
- Return on Equity (ROE) of 12.1% signifies efficient utilization of shareholder equity to generate profits.
- Debt-to-equity ratio of 70.09% suggests a moderate level of financial leverage.
Competitors & Peers
Strengths
- Strong brand recognition in the Swiss healthcare market.
- Integrated healthcare service model.
- Extensive distribution network.
- Specialized expertise in pre-wholesale services.
Weaknesses
- Reliance on the Swiss market.
- Exposure to regulatory changes in the healthcare industry.
- Competition from larger pharmaceutical companies.
- Potential for supply chain disruptions.
Catalysts
- Upcoming: Expansion of pharmacy network through strategic acquisitions and partnerships.
- Ongoing: Increasing demand for logistics and IT services from pharmaceutical companies.
- Ongoing: Development and launch of new digital healthcare solutions.
- Ongoing: Expansion of personalized medicine and diagnostic services.
- Upcoming: Potential regulatory changes in the Swiss healthcare market.
Risks
- Potential: Intense competition in the Swiss healthcare market.
- Potential: Economic downturn affecting consumer spending on healthcare.
- Ongoing: Changes in government regulations and reimbursement policies.
- Potential: Emergence of new technologies disrupting the healthcare industry.
- Ongoing: Limited liquidity due to trading on the OTC market.
Growth Opportunities
- Expansion of Pharmacy Network: Galenica AG can grow by expanding its pharmacy network under the Amavita, Sun Store, and Coop Vitality brands. The Swiss pharmacy market is valued at several billion dollars annually. Strategic acquisitions and partnerships with independent pharmacies can accelerate this growth. The timeline for expansion is ongoing, with continuous efforts to increase market share and geographic reach. This expansion will allow Galenica to capture a larger share of the retail pharmacy market and enhance its brand presence.
- Increased Demand for Logistics and IT Services: The Logistics & IT segment can benefit from the increasing demand for specialized pre-wholesale services in the pharmaceutical industry. This includes storage, distribution, and debt collection. The market for pharmaceutical logistics is growing due to the increasing complexity of supply chains and regulatory requirements. Galenica's expertise in this area provides a competitive advantage. The timeline for growth is immediate, with ongoing efforts to secure new contracts and expand service offerings.
- Development of Digital Healthcare Solutions: Galenica AG can capitalize on the growing trend of digital healthcare by developing and offering innovative digital solutions. This includes telemedicine platforms, mobile health apps, and online pharmacy services. The market for digital healthcare is rapidly expanding, driven by increasing internet penetration and patient demand for convenient healthcare options. Galenica's existing infrastructure and customer base provide a strong foundation for this growth. The timeline for development is ongoing, with continuous investment in research and development.
- Personalized Medicine and Diagnostic Services: The company can further expand its personalized medicine and diagnostic services, including laboratory medicine, pathology, and specialized personalized diagnostic services. The market for personalized medicine is growing due to advancements in genomics and precision medicine. Galenica's expertise in this area allows it to offer tailored treatment options and improve patient outcomes. The timeline for expansion is ongoing, with continuous efforts to develop new diagnostic tests and personalized treatment plans.
- Strategic Partnerships and Acquisitions: Galenica AG can pursue strategic partnerships and acquisitions to expand its service offerings and geographic reach. This includes partnering with other healthcare providers, technology companies, and pharmaceutical manufacturers. Strategic acquisitions can provide access to new markets, technologies, and customer segments. The timeline for partnerships and acquisitions is ongoing, with continuous evaluation of potential opportunities. These partnerships and acquisitions will allow Galenica to enhance its competitive position and drive long-term growth.
Opportunities
- Expansion into new geographic markets.
- Development of digital healthcare solutions.
- Strategic partnerships and acquisitions.
- Increased demand for personalized medicine.
Threats
- Intense competition in the healthcare sector.
- Economic downturn affecting consumer spending on healthcare.
- Changes in government regulations and reimbursement policies.
- Emergence of new technologies disrupting the healthcare industry.
Competitive Advantages
- Established brand recognition with well-known pharmacy brands like Amavita and Sun Store.
- Integrated healthcare service model combining pharmacy operations with logistics and IT services.
- Extensive distribution network providing efficient delivery services.
- Specialized expertise in pre-wholesale services for the pharmaceutical industry.
About GALNF
Founded in 1927 and headquartered in Bern, Switzerland, Galenica AG has evolved into a prominent healthcare service provider. The company operates through two primary segments: Products & Care and Logistics & IT. The Products & Care segment manages a network of pharmacies and partner pharmacies under well-known brands such as Amavita, Sun Store, and Coop Vitality. This segment also includes mediservice, a specialty pharmacy, and offers medication for home treatment, laboratory medicine, pathology, and personalized diagnostic services. Galenica develops, markets, and sells healthcare services and products through various distribution channels, catering to a wide range of patient needs. The Logistics & IT segment provides specialized pre-wholesale services, including storage, distribution, and debt collection, to pharmaceutical and healthcare companies. It also develops management solutions for the healthcare market, publishes technical information on pharmaceutical products, and offers complete management solutions for pharmacies. Galenica's comprehensive service offerings and established market presence have solidified its position as a key player in the Swiss healthcare landscape.
What They Do
- Operates and manages pharmacies under the Amavita, Sun Store, and Coop Vitality brands.
- Provides specialty pharmacy services through mediservice.
- Offers medication for treatment of patients at home.
- Provides laboratory medicine, pathology, and specialized personalized diagnostic services.
- Develops, markets, and sells healthcare services and products through various distribution channels.
- Provides specialized pre-wholesale services, including storage, distribution, and debt collection, to pharmaceutical and healthcare companies.
- Develops management solutions for the healthcare market.
- Publishes printed and electronic technical information on pharmaceutical products.
Business Model
- Revenue from pharmacy sales and services.
- Income from logistics and IT services provided to pharmaceutical companies.
- Sales of healthcare products through various distribution channels.
- Fees from laboratory medicine, pathology, and diagnostic services.
Industry Context
Galenica AG operates within the healthcare sector, specifically in medical distribution and pharmacy services. The Swiss healthcare market is characterized by high standards and a focus on quality. The company's integrated approach, combining pharmacy operations with logistics and IT services, positions it favorably in this competitive landscape. Market trends include increasing demand for personalized medicine and digital healthcare solutions. Galenica's established network and comprehensive service offerings enable it to capitalize on these trends and maintain a competitive edge.
Key Customers
- Individual patients seeking pharmaceutical products and healthcare services.
- Pharmaceutical companies requiring logistics and IT solutions.
- Pharmacies and drugstores utilizing Galenica's management solutions.
- Doctors, hospitals, and care homes receiving on-schedule delivery services.
Financials
Chart & Info
Galenica AG (GALNF) stock price: Price data unavailable
Latest News
No recent news available for GALNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GALNF.
Price Targets
Wall Street price target analysis for GALNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GALNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
GALNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Galenica AG may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited reporting requirements and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history or those that are thinly traded.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to major exchanges.
- Less stringent reporting requirements, potentially leading to information asymmetry.
- Higher price volatility due to lower trading volume.
- Potential for scams and fraudulent schemes on the OTC market.
- Lack of regulatory oversight compared to listed companies.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Monitor trading volume and price volatility.
- Consult with a financial advisor or conduct thorough research before investing.
- Understand the risks associated with investing in OTC stocks.
- Established operating history since 1927.
- Presence in a regulated industry (healthcare).
- Significant employee base (4,727 employees).
- Substantial market capitalization ($6.17B).
- Operations in Switzerland, a country with strong corporate governance standards.
Common Questions About GALNF
What does Galenica AG do?
Galenica AG is a leading healthcare service provider in Switzerland, operating through two main segments: Products & Care and Logistics & IT. The Products & Care segment manages pharmacies under brands like Amavita and Sun Store, offering pharmaceutical products and healthcare services directly to consumers. The Logistics & IT segment provides specialized pre-wholesale services, including storage, distribution, and IT solutions, to pharmaceutical companies. This integrated approach allows Galenica to serve as a comprehensive partner in the healthcare ecosystem, from manufacturing support to direct patient care.
What do analysts say about GALNF stock?
As of 2026-03-16, a comprehensive analyst consensus for GALNF is pending AI analysis. Key valuation metrics include a market capitalization of $6.17 billion, a profit margin of 4.4%, and a return on equity of 12.1%. Growth considerations revolve around the company's ability to expand its pharmacy network, capitalize on the increasing demand for logistics and IT services, and develop innovative digital healthcare solutions. Investors should monitor these factors to assess the stock's potential performance.
What are the main risks for GALNF?
Galenica AG faces several risks, including intense competition in the Swiss healthcare market, potential economic downturns affecting consumer spending on healthcare, and changes in government regulations and reimbursement policies. The emergence of new technologies could also disrupt the healthcare industry, requiring Galenica to adapt and innovate. Additionally, as the company trades on the OTC market, it faces risks associated with limited liquidity and less stringent reporting requirements compared to companies listed on major exchanges.
What are the key factors to evaluate for GALNF?
Galenica AG (GALNF) currently holds an AI score of 46/100, indicating low score. Key strength: Strong brand recognition in the Swiss healthcare market.. Primary risk to monitor: Potential: Intense competition in the Swiss healthcare market.. This is not financial advice.
How frequently does GALNF data refresh on this page?
GALNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GALNF's recent stock price performance?
Recent price movement in Galenica AG (GALNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition in the Swiss healthcare market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GALNF overvalued or undervalued right now?
Determining whether Galenica AG (GALNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GALNF?
Before investing in Galenica AG (GALNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be limited or delayed.
- AI analysis pending for GALNF.